Spiro Medical is developing a purpose-built pulmonary neuromodulation system for patients with severe asthma. The company sits at the intersection of implantable neuromodulation, respiratory medicine, and bioelectronic medicine, with a focus on the role of airway nerves and neural reflex pathways in asthma symptoms.

The system is intended to modulate neural pathways involved in wheezing, shortness of breath, chest tightness, and coughing. Public materials describe a purpose-built pulmonary neuromodulation system supported by issued patents, preliminary human data, and planned clinical work for U.S. regulatory approval.

Spiro targets severe asthma as its initial clinical indication, while adjacent breathing-related conditions may provide a broader platform path over time. The company raised a $67 million Series A in 2026 to develop the syxstem and support the clinical work required for U.S. regulatory review.